Publications 2024

Brun MK, Gehin JE, Bjørlykke KH, Warren DJ, Klaasen RA, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Jahnsen J, Bolstad N, Jørgensen KK, Haavardsholm EA, Goll GL, Syversen SW (2024)
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Lancet Rheumatol, 6 (4), e226-e236
DOI 10.1016/S2665-9913(23)00341-7, PubMed 38402891

Kong XY, Lauritzen KH, Dahl TB, Holm S, Olsen MB, Skjelland M, Nielsen C, Michelsen AE, Ueland T, Aukrust P, Halvorsen B, Sandanger Ø (2024)
CD38 deficient mice are not protected from atherosclerosis
Biochem Biophys Res Commun, 705, 149734
DOI 10.1016/j.bbrc.2024.149734, PubMed 38430607

Publications 2023

Brun MK, Bjørlykke KH, Viken MK, Stenvik GE, Klaasen RA, Gehin JE, Warren DJ, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Haavardsholm EA, Jahnsen J, Goll GL, Lie BA, Bolstad N, Jørgensen KK, Syversen SW (2023)
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases
J Intern Med, 293 (5), 648-655
DOI 10.1111/joim.13616, PubMed 36843323

Publications 2022

Brun MK, Goll GL, Jørgensen KK, Sexton J, Gehin JE, Sandanger Ø, Olsen IC, Klaasen RA, Warren DJ, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA, Syversen SW (2022)
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
J Intern Med, 292 (3), 477-491
DOI 10.1111/joim.13495, PubMed 35411981

Publications 2021

Olsen MB, Gregersen I, Sandanger Ø, Yang K, Sokolova M, Halvorsen BE, Gullestad L, Broch K, Aukrust P, Louwe MC (2021)
Targeting the Inflammasome in Cardiovascular Disease
JACC Basic Transl Sci, 7 (1), 84-98
DOI 10.1016/j.jacbts.2021.08.006, PubMed 35128212

Syversen SW, Goll GL, Jørgensen KK, Sandanger Ø, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljoså MKA, Haugen AJ, Njålla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune T et al. (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 325 (17), 1744-1754
DOI 10.1001/jama.2021.4172, PubMed 33944876

Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM et al. (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 326 (23), 2375-2384
DOI 10.1001/jama.2021.21316, PubMed 34932077

Publications 2020

Niyonzima N, Bakke SS, Gregersen I, Holm S, Sandanger Ø, Orrem HL, Sporsheim B, Ryan L, Kong XY, Dahl TB, Skjelland M, Sørensen KK, Rokstad AM, Yndestad A, Latz E, Gullestad L, Andersen GØ, Damås JK, Aukrust P, Mollnes TE, Halvorsen B, Espevik T (2020)
Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis
EBioMedicine, 60, 102985
DOI 10.1016/j.ebiom.2020.102985, PubMed 32927275

Syversen SW, Goll GL, Jørgensen KK, Olsen IC, Sandanger Ø, Gehin JE, Warren DJ, Sexton J, Mørk C, Jahnsen J, Kvien TK, Bolstad N, Haavardsholm EA (2020)
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
Trials, 21 (1), 13
DOI 10.1186/s13063-019-3734-4, PubMed 31907007

Publications 2019

Torp MK, Yang K, Ranheim T, Husø Lauritzen K, Alfsnes K, Vinge LE, Aukrust P, Stensløkken KO, Yndestad A, Sandanger Ø (2019)
Mammalian Target of Rapamycin (mTOR) and the Proteasome Attenuates IL-1β Expression in Primary Mouse Cardiac Fibroblasts
Front Immunol, 10, 1285
DOI 10.3389/fimmu.2019.01285, PubMed 31244838

Yang K, Lauritzen KH, Olsen MB, Dahl TB, Ranheim T, Ahmed MS, Attramadal H, Aukrust P, Halvorsen B, Nyman TA, Sandanger Ø, Yndestad A (2019)
Low Cellular NAD⁺ Compromises Lipopolysaccharide-Induced Inflammatory Responses via Inhibiting TLR4 Signal Transduction in Human Monocytes
J Immunol, 203 (6), 1598-1608
DOI 10.4049/jimmunol.1801382, PubMed 31427442

Publications 2017

Dhondup Y, Sjaastad I, Sandanger Ø, Aronsen JM, Ahmed MS, Attramadal H, Finsen AV, Zhang L, Ranheim T, Alfsnes K, Aukrust P, Christensen G, Yndestad A, Vinge LE (2017)
Toll-Like Receptor 9 Promotes Survival in SERCA2a KO Heart Failure Mice
Mediators Inflamm, 2017, 9450439
DOI 10.1155/2017/9450439, PubMed 28490840

Gregersen I, Sandanger Ø, Askevold ET, Sagen EL, Yang K, Holm S, Pedersen TM, Skjelland M, Krohg-Sørensen K, Hansen TV, Dahl TB, Otterdal K, Espevik T, Aukrust P, Yndestad A, Halvorsen B (2017)
Interleukin 27 is increased in carotid atherosclerosis and promotes NLRP3 inflammasome activation
PLoS One, 12 (11), e0188387
DOI 10.1371/journal.pone.0188387, PubMed 29176764

Publications 2016

Dhondup Y, Ueland T, Dahl CP, Askevold ET, Sandanger Ø, Fiane A, Ohm IK, Sjaastad I, Finsen AV, Wæhre A, Gullestad L, Aukrust P, Yndestad A, Vinge LE (2016)
Low Circulating Levels of Mitochondrial and High Levels of Nuclear DNA Predict Mortality in Chronic Heart Failure
J Card Fail, 22 (10), 823-8
DOI 10.1016/j.cardfail.2016.06.013, PubMed 27349571

Sokolova M, Vinge LE, Alfsnes K, Olsen MB, Eide L, Kaasbøll OJ, Attramadal H, Torp MK, Fosshaug LE, Rashidi A, Lien E, Finsen AV, Sandanger Ø, Aukrust P, Ranheim T, Yndestad A (2016)
Palmitate promotes inflammatory responses and cellular senescence in cardiac fibroblasts
Biochim Biophys Acta Mol Cell Biol Lipids, 1862 (2), 234-245
DOI 10.1016/j.bbalip.2016.11.003, PubMed 27845246

Yndestad A, Sandanger Ø, Jong WMC, Aukrust P, Zuurbier CJ (2016)
Response to letter from Toldo et al. on "NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective"
Biochem Biophys Res Commun, 474 (2), 328-329
DOI 10.1016/j.bbrc.2016.04.096, PubMed 27109473

Publications 2015

Dhondup Y, Sjaastad I, Scott H, Sandanger Ø, Zhang L, Haugstad SB, Aronsen JM, Ranheim T, Holmen SD, Alfsnes K, Ahmed MS, Attramadal H, Gullestad L, Aukrust P, Christensen G, Yndestad A, Vinge LE (2015)
Sustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO Mice
PLoS One, 10 (10), e0139715
DOI 10.1371/journal.pone.0139715, PubMed 26461521

Sandanger Ø, Gao E, Ranheim T, Bliksøen M, Kaasbøll OJ, Alfsnes K, Nymo SH, Rashidi A, Ohm IK, Attramadal H, Aukrust P, Vinge LE, Yndestad A (2015)
NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective
Biochem Biophys Res Commun, 469 (4), 1012-20
DOI 10.1016/j.bbrc.2015.12.051, PubMed 26706279

Publications 2014

Huber-Lang M, Barratt-Due A, Pischke SE, Sandanger Ø, Nilsson PH, Nunn MA, Denk S, Gaus W, Espevik T, Mollnes TE (2014)
Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice
J Immunol, 192 (11), 5324-31
DOI 10.4049/jimmunol.1400341, PubMed 24790148

Ohm IK, Alfsnes K, Belland Olsen M, Ranheim T, Sandanger Ø, Dahl TB, Aukrust P, Finsen AV, Yndestad A, Vinge LE (2014)
Toll-like receptor 9 mediated responses in cardiac fibroblasts
PLoS One, 9 (8), e104398
DOI 10.1371/journal.pone.0104398, PubMed 25126740

Publications 2013

Sandanger Ø, Ranheim T, Vinge LE, Bliksøen M, Alfsnes K, Finsen AV, Dahl CP, Askevold ET, Florholmen G, Christensen G, Fitzgerald KA, Lien E, Valen G, Espevik T, Aukrust P, Yndestad A (2013)
The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury
Cardiovasc Res, 99 (1), 164-74
DOI 10.1093/cvr/cvt091, PubMed 23580606

Sandanger Ø, Ranheim T, Vinge LE, Bliksøen M, Valen G, Aukrust P, Yndestad A (2013)
A role for NLRP3 inflammasome in acute myocardial ischaemia-reperfusion injury? Reply
Cardiovasc Res, 99 (1), 226-7
DOI 10.1093/cvr/cvt130, PubMed 23708737

Publications 2012

Yndestad A, Finsen AV, Ueland T, Husberg C, Dahl CP, Øie E, Vinge LE, Sjaastad I, Sandanger Ø, Ranheim T, Dickstein K, Kjekshus J, Damås JK, Fiane AE, Hilfiker-Kleiner D, Lipp M, Gullestad L, Christensen G, Aukrust P (2012)
The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure
PLoS One, 7 (3), e33038
DOI 10.1371/journal.pone.0033038, PubMed 22427939

Ørn S, Ueland T, Manhenke C, Sandanger Ø, Godang K, Yndestad A, Mollnes TE, Dickstein K, Aukrust P (2012)
Increased interleukin-1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention
J Intern Med, 272 (3), 267-76
DOI 10.1111/j.1365-2796.2012.02517.x, PubMed 22243053

Publications 2011

Grimstad Ø, Sandanger Ø, Ryan L, Otterdal K, Damaas JK, Pukstad B, Espevik T (2011)
Cellular sources and inducers of cytokines present in acute wound fluid
Wound Repair Regen, 19 (3), 337-47
DOI 10.1111/j.1524-475X.2011.00668.x, PubMed 21371163

Publications 2009

Sandanger Ø, Ryan L, Bohnhorst J, Iversen AC, Husebye H, Halaas Ø, Landrø L, Aukrust P, Frøland SS, Elson G, Visintin A, Øktedalen O, Damås JK, Sundan A, Golenbock D, Espevik T (2009)
IL-10 enhances MD-2 and CD14 expression in monocytes and the proteins are increased and correlated in HIV-infected patients
J Immunol, 182 (1), 588-95
DOI 10.4049/jimmunol.182.1.588, PubMed 19109192

Publications 2006

Husebye H, Halaas Ø, Stenmark H, Tunheim G, Sandanger Ø, Bogen B, Brech A, Latz E, Espevik T (2006)
Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity
EMBO J, 25 (4), 683-92
DOI 10.1038/sj.emboj.7600991, PubMed 16467847